期刊
TRANSLATIONAL STROKE RESEARCH
卷 10, 期 4, 页码 381-388出版社
SPRINGER
DOI: 10.1007/s12975-018-0650-y
关键词
Cerebral infarction; Cerebral vasospasm; Cilostazol; Delayed cerebral ischemia; Subarachnoid hemorrhage; Tenascin-C
资金
- Japan Society for the Promotion of Science [17K10825]
- Grants-in-Aid for Scientific Research [17K10825] Funding Source: KAKEN
Cilostazol is a selective inhibitor of phosphodiesterase type III that downregulates tenascin-C (TNC), a matricellular protein, which may cause delayed cerebral infarction after aneurysmal subarachnoid hemorrhage (SAH). The authors increased the dosage and evaluated the dose-dependent effects of cilostazol on delayed cerebral infarction and outcomes in SAH patients. This was a retrospective cohort study in a single center. One hundred fifty-six consecutive SAH patients including 67 patients of admission World Federation of Neurological Surgeons grades IV-V who underwent aneurysmal obliteration within 48h post-SAH from 2007 to 2017 were analyzed. Cilostazol (0 to 300mg/day) was administered from 1-day post-clipping or post-coiling to day 14 or later. Cilostazol treatment dose-dependently decreased delayed cerebral infarction and tended to improve outcomes, although cilostazol did not affect other outcome measures including angiographic vasospasm. On multivariate analyses, 300mg/day (100mg three times) cilostazol independently decreased delayed cerebral infarction and improved 3-month outcomes, but other regimens including 200mg/day (100mg twice) cilostazol were not independent prognostic factors. Propensity score-matched analyses showed that the 300mg/day cilostazol cohort had lower plasma TNC levels and a lower incidence of delayed cerebral infarction associated with better outcomes compared with the non-cilostazol cohort. The 300mg/day cilostazol may improve post-SAH outcomes by reducing plasma TNC levels and delayed cerebral infarction, but not vasospasm. Further studies are warranted to investigate if 300mg/day cilostazol is more beneficial to post-SAH outcomes than a usual dose of 200mg/day cilostazol that was demonstrated to be effective in randomized controlled trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据